Tekmira Pharmaceuticals Corporation
TSX : TKM

Tekmira Pharmaceuticals Corporation

February 04, 2010 16:30 ET

Tekmira Pharmaceuticals to Present at 12th Annual BIO CEO & Investor Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 4, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics and proprietary delivery technology, announced today that the Company's President and Chief Executive Officer, Dr. Mark Murray, will present a corporate overview at the 2010 BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 2:00 p.m. ET.

Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City.

A live webcast of the presentation will be available on the Company's website, www.tekmirapharm.com. A replay of the presentation will be available for 90 days.

In addition to the presentation, Dr. Murray will participate in a therapeutic panel titled "RNAi-Based Technologies: No Longer Single & Stranded". The one-hour panel discussion will take place on February 8, 2010 at 3:00 p.m. ET and is open to conference registrants only. The panel discussion will not be webcast.

About RNAi and SNALP

RNAi drugs have the potential to treat human diseases by "switching-off" disease causing genes. The technology, representing one of the most promising and rapidly advancing frontiers in biology and drug discovery, was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi drugs, such as siRNA, require delivery technology to be administered systemically. In preclinical studies, Tekmira's SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites. Tekmira believes it has a leading intellectual property position in the field of siRNA delivery.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

About the BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit www.ceo.bio.org.

Contact Information